Anthony M. D’Amelio

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard, Egbert F. Smit, Harry J.M. Groen et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +11

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

David Planchard, Benjamin Besse, Harry J.M. Groen et al. · The Lancet Oncology · 2016 · 878 citations · Full text

Medicine, Oncology, Pharmacology +12

Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

David Planchard, Tae Min Kim, Julien Mazières et al. · The Lancet Oncology · 2016 · 444 citations · Full text

Medicine, Oncology, Pharmacology +8

GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma

Jorge A. Marrero, Patrick R. Romano, Laura Steel et al. · Journal of Hepatology · 2005 · 363 citations

Medicine, Molecular Biology, Oncology +13

Development and Validation of a Lung Cancer Risk Prediction Model for African-Americans

Carol J. Etzel, Sumesh Kachroo, Mei Liu et al. · Cancer Prevention Research · 2008 · 119 citations · Full text

Medicine, Biostatistics, Oncology +17